Keith Abe
Millennium Pharmaceuticals
12 Papers
109 Citations
Keith Abe is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Platelet-derived growth factor receptor & Growth factor receptor. The author has an hindex of 10, co-authored 12 publications.
Chat about Author
Papers
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
Genmin Lu,Francis DeGuzman,Stanley J. Hollenbach,Mark Karbarz,Keith Abe,Gail Lee,Peng Luan,Athiwat Hutchaleelaha,Mayuko Inagaki,Pamela B. Conley,David Phillips,Uma Sinha +11 more
TL;DR: In this article, a modified form of coagulation factor Xa (fXa) was used as an antidote for fXa inhibitors and corrected the prolongation of ex vivo clotting times by such inhibitors.
735
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Louise M Kelly,Louise M Kelly,Jin-Chen Yu,Christina L. Boulton,Mutiah Apatira,Jason Li,Carol M. Sullivan,Ifor R. Williams,Sonia M Amaral,Sonia M Amaral,David P. Curley,Nicole Duclos,Nicole Duclos,Donna Neuberg,Robert M. Scarborough,Anjali Pandey,Stanley J. Hollenbach,Keith Abe,Nathalie Lokker,D. Gary Gilliland,D. Gary Gilliland,Neill A. Giese +21 more
TL;DR: CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor (PDGFR), and c-Kit, and inhibitedFLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways, was developed.
372
Platelet and osteoclast β3 integrins are critical for bone metastasis
Suzanne J. Bakewell,Patrick Nestor,Srinivasa K. Prasad,Michael H. Tomasson,Nikki Dowland,Mukund Mehrotra,Robert M. Scarborough,James Kanter,Keith Abe,David R. Phillips,Katherine N. Weilbaecher +10 more
TL;DR: A critical role for platelet αIIbβ3 in tumor entry into bone is demonstrated and a mechanism by which antiplatelet therapy may be beneficial in preventing the metastasis of solid tumors is suggested.
240
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Anjali Pandey,Deborah Volkots,Joseph M. Seroogy,Jack W. Rose,Jin-Chen Yu,Joseph L. Lambing,Athiwat Hutchaleelaha,Stanley J. Hollenbach,Keith Abe,Neill A. Giese,Robert M. Scarborough +10 more
TL;DR: Oral administration of 75 promotes mice survival and significantly delayed disease progression in a Flt-3/ITD-mediated leukemia mouse model and shows efficacy in a nude mouse model of chronic myelomonocytic leukemia.
143
Patent
Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
Uma Sinha,Stanley J. Hollenbach,Keith Abe +2 more
- 15 Nov 2007
TL;DR: In this article, the unit dose of the factor Xa inhibitor compound required to inhibit coagulation in a primate is lower than the unit dosage required to obtain similar levels of inhibition in other animal models, such as rodents.
38